Latest filing published 17 Feb 2023 for Syndax Pharmaceuticals Inc, €45k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Peter Ordentlich: trading record in brief
Peter Ordentlich (senior executive) discloses dealings in Syndax Pharmaceuticals Inc to SEC (Form 4). Between 17 May 2017 and 15 February 2023, the trades on record add up to 28 filings.
No open-market purchase appears, only 14 sales worth €2.6M. Besides market trades, the filings include 11 option exercises. Since January 2023: no purchases and 3 sales on the market.
The latest filing, published on 17 February 2023, reports an open-market sale of €182k in Syndax Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Peter Ordentlich
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,572 shares@ US$6.3861.9% of flowCommon StockSEC:0001562180-23-001533:0
- 69 shares@ US$17.321.5% of flowCommon StockSEC:0001562180-23-000950:0
- 3,772 shares@ US$6.3531.6% of flowCommon StockSEC:0001562180-22-008017:0
- 265 shares@ US$14.125.0% of flowCommon StockSEC:0001562180-22-006334:0
- 1,412 shares@ US$12.39100.0% of flowCommon StockSEC:0001562180-22-001079:0
5 of 5 declarations
